aTyr Pharma, Inc. (ATYR)
3.82
+0.13
(+3.52%)
USD |
NASDAQ |
Nov 20, 16:00
3.80
-0.02
(-0.52%)
After-Hours: 20:00
aTyr Pharma Shareholders Equity (Quarterly) : 33.98M for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 33.98M |
| June 30, 2026 | 48.79M |
| March 31, 2026 | 57.93M |
| December 31, 2025 | 67.48M |
| September 30, 2025 | 80.24M |
| June 30, 2025 | 74.84M |
| March 31, 2025 | 75.05M |
| December 31, 2024 | 70.02M |
| September 30, 2024 | 65.32M |
| June 30, 2024 | 81.61M |
| March 31, 2024 | 84.47M |
| December 31, 2023 | 90.66M |
| September 30, 2023 | 98.39M |
| June 30, 2023 | 106.24M |
| March 31, 2023 | 109.88M |
| December 31, 2022 | 71.46M |
| September 30, 2022 | 77.18M |
| June 30, 2022 | 86.64M |
| March 31, 2022 | 98.55M |
| December 31, 2021 | 109.30M |
| September 30, 2021 | 117.61M |
| June 30, 2021 | 40.98M |
| March 31, 2021 | 49.70M |
| December 31, 2020 | 31.65M |
| Date | Value |
|---|---|
| September 30, 2020 | 32.16M |
| June 30, 2020 | 36.10M |
| March 31, 2020 | 42.13M |
| December 31, 2019 | 21.19M |
| September 30, 2019 | 26.74M |
| June 30, 2019 | 30.23M |
| March 31, 2019 | 29.48M |
| December 31, 2018 | 33.65M |
| September 30, 2018 | 38.99M |
| June 30, 2018 | 45.38M |
| March 31, 2018 | 54.50M |
| December 31, 2017 | 64.24M |
| September 30, 2017 | 72.29M |
| June 30, 2017 | 40.03M |
| March 31, 2017 | 50.71M |
| December 31, 2016 | 62.80M |
| September 30, 2016 | 73.99M |
| June 30, 2016 | 86.57M |
| March 31, 2016 | 100.43M |
| December 31, 2015 | 115.05M |
| September 30, 2015 | 129.16M |
| June 30, 2015 | 139.34M |
| March 31, 2015 | 43.29M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.387B |
| Alnylam Pharmaceuticals, Inc. | 3.604B |
| Anika Therapeutics, Inc. | 137.58M |
| Savara, Inc. | 107.85M |
| Arrowhead Pharmaceuticals, Inc. | 50.31M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 59.81M |
| Total Liabilities (Quarterly) | 26.01M |
| Debt to Equity Ratio | 0.3213 |
| Current Ratio | 3.047 |
| Net Debt Paydown Yield | 1.16% |